obtructive hypertrophic cardiomyopathy

BMS builds case for mavacamten label ahead of FDA decision
Pharmaforum
Thu, 02/17/22 - 11:01 am
Bristol Myers Squibb
mavacamten
obtructive hypertrophic cardiomyopathy
MyoKardia
FDA